Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04138758 · ClinicalTrials.gov registry record
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 42,953
- Enrollment target
NCT04138758 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 42,953 participants.
The verdict
NCT04138758 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 42,953 participants
- Enrollment target
Study Summary
The primary objective is to compare the effectiveness of maintenance therapy initiation with the combination treatment Tiotropium and Olodaterol (Olo+Tio) compared with LABA/ICS combination in COPD as the time to the first COPD exacerbation. Secondary objectives are to compare patients treated with Tio+Olo and patients treated with LABA/ ICS combination.
Interventions
- DRUG Tiotropium bromide + Olodaterol
- DRUG LABA/ICS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42,953 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2019-11-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04138758
The ClinicalTrials.gov registry entry for NCT04138758 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42,953 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium bromide + Olodaterol is the first listed.
NCT04138758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04138758 about?
NCT04138758 is a clinical study titled "Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS". The primary objective is to compare the effectiveness of maintenance therapy initiation with the combination treatment Tiotropium and Olodaterol (Olo+Tio) compared with LABA/ICS combination in COPD as the time to the first COPD exacerbation. Secondary objectives are to compare patients treated with...
What is the current status of trial NCT04138758?
This trial is currently completed. The enrollment target is 42,953 participants. The study started on 2019-11-01. Estimated completion is 2019-11-04.
What interventions are being tested in trial NCT04138758?
The interventions under investigation include: Tiotropium bromide + Olodaterol (DRUG), LABA/ICS (DRUG).
Who is sponsoring clinical trial NCT04138758?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.